9,900 Results

E 2006 filed with FDA for insomnia sleep-wake disorder.- Eisai.

 Added 15 hours ago

Eisai announced that a new drug application has been submitted to the FDA for E 2006 (lemborexant), an investigational agent...

FDA approves expanded indication for Adacel in Tdap.- Sanofi Pasteur.

 Added 15 hours ago

The FDA has approved the expanded use of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)...

Updated results from Phase III BEACON CRC trial evaluating Braftovi + Mektovi + Erbitux for BRAFV600E-mutant colorectal cancer.- Array Biopharma

 Added 15 hours ago

Array Biopharma announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase...

FDA approves Amplatzer Piccolo Occluder to treat patent ductus arteriosus. Abbott

 Added 1 day ago

Abbott announced the FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the...

European Commission approves Opdivo + Yervoy ( low dose) for first line treatment of renal cell carcinoma.- BMS

 Added 1 day ago

Bristol-Myers Squibb Company announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab)...

Vyndaqel filed with FDA for transthyretin amyloid cardiomyopathy.- Pfizer.

 Added 1 day ago

Pfizer announced that the FDA accepted for filing the company’s New Drug Applications (NDAs) for Vyndaqel (tafamidis) for the treatment...

EUSA Pharma acquires world rights to Sylvant to treat Castleman’s disease.

 Added 3 days ago

EUSA Pharma announced that it has successfully completed the acquisition of the worldwide rights to Sylvant (siltuximab) from Janssen Sciences...

Aeglea BioTherapeutics initiates phase III PEACE study for pegzilarginase to treat Arginase 1 Deficiency.

 Added 4 days ago

Aeglea BioTherapeutics, Inc. announced the design of its global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical...

Dextenza filed with FDA for ocular inflammation post surgery.- Ocular Therapeutix.

 Added 5 days ago

Ocular Therapeutix announced the submission of a supplemental New Drug Application (sNDA) to the FDA for Dextenza (dexamethasone ophthalmic insert)....

Draft NICE guidance does not recommend Aimovig in migraine.- Novartis.

 Added 5 days ago

In draft guidelines, the National Institute for Health and Care Excellence (NICE) has announced that it has decided that Aimovig...

Load more